Business Wire

CA-KENAI-THERAPEUTICS

Share
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. Kenai Therapeutics previously raised seed funding under the name Ryne Bio.

“We are grateful for the support of a syndicate of leading life science investors and a team of industry veterans, including scientific co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower, who see the promise in Kenai’s approach to treating central nervous system disorders,” said Nick Manusos, chief executive officer of Kenai Therapeutics. “Their guidance will be invaluable as we soon advance our lead candidate, RNDP-001, into the clinic for the treatment of Parkinson’s disease.”

RNDP-001 is an iPSC-derived, allogeneic dopamine progenitor cell therapy for the treatment of both idiopathic and inherited forms of Parkinson’s disease, and has displayed robust survival, innervation, and behavioral rescue in preclinical models of Parkinson’s disease. Proceeds from the financing will enable the Company to submit an IND for RNDP-001 and complete Phase 1 clinical trials, which will initiate within the year.

“Kenai’s proprietary platform leverages an emerging approach to treating central nervous system disorders by replacing neurons lost due to neurodegeneration,” said Jeff Jonas, M.D., chair and board member of Kenai Therapeutics and partner at Cure Ventures. “The potentially curative nature of RNDP-001 for Parkinson’s disease could dramatically alter outcomes for patients with very few treatment options.”

Beyond RNDP-001, Kenai is developing a robust pipeline of advanced off-the-shelf dopamine neuron replacement cell therapeutics for neurological disorders. The Company will continue to work with its contract manufacturing partner, FUJIFILM Cellular Dynamics, a leading expert in iPSC technology and research, for manufacturing and development services.

“As a global leader in the field of iPSCs, we are thrilled to support the Kenai Therapeutics team to achieve progress in this promising area of science for patients with neurodegenerative diseases,” said Tomoyuki Hasegawa, president and chief executive officer at FUJIFILM Cellular Dynamics, Inc.

“Kenai’s approach to treating Parkinson’s disease is meaningfully differentiated from competing cell therapy approaches and has disease-modifying potential for patients with limited, primarily symptomatic, treatment options,” said Jeff Goater, partner at The Column Group. “We are proud to be able to support Kenai in its mission to advance RNDP-001 to help families and patients suffering with this devastating disease.”

About Kenai Therapeutics

Kenai Therapeutics (Kenai) is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture many human cell types, in order to advance Kenai’s off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological diseases. For additional information, please visit: www.kenaitx.com.

About Alaska Permanent Fund Corporation

The Alaska Permanent Fund Corporation (APFC) was created by the Alaska Legislature in 1980 as a quasi-independent state entity tasked with the important mission of prudently investing and managing the assets of the Alaska Permanent Fund. The Fund’s total assets are approximately $80 billion and are invested across a broad range of assets including equities, fixed income, alternatives and real estate. The Fund has been an active investor in biotechnology and life sciences dating back to 2013 and these assets now represent approximately 8% of APFC’s $15 billion private equity portfolio. For more information, please visit: www.apfc.org.

About Cure Ventures

Founded in 2021, Cure Ventures is a life sciences venture capital firm focusing on de novo company formation around groundbreaking curative technologies. Above all else, the Cure team leads with respect for people and for science. Led by highly accomplished industry veterans, Cure’s investment thesis is founded on three tenets: A seed funding model that allows Cure to de-risk the science and set companies up for success; genetic validation that increases the probability of success; and embedded Cure operators to drive the best day-to-day decision making in collaboration with founders. For more information, please visit: www.curevc.com.

About The Column Group

The Column Group (TCG) is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complimentary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas. For more information, please visit: www.thecolumngroup.com.

About FUJIFILM Cellular Dynamics, Inc.

FUJIFILM Cellular Dynamics, Inc. is a leading developer and manufacturer of human iPSCs and iPSC-derived cells utilized in drug discovery, contract development and manufacturing services for cell therapies. For its partners, FUJIFILM Cellular Dynamics utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FUJIFILM Cellular Dynamics also offers life science research tools including the company’s inventoried iCell® products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell services and cell banking. FUJIFILM Cellular Dynamics’ goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit: www.fujifilmcdi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229997334/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Settles Pending Litigation13.2.2025 13:00:00 CET | Press release

Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain orchestration, has entered into a settlement agreement with Blue Yonder Group, Inc. to fully resolve all pending litigation matters between the companies which includes Blue Yonder’s patent infringement claims and Kinaxis’ trade secret misappropriation counterclaims. The terms of the settlement agreement are confidential. About Kinaxis Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please

Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts13.2.2025 13:00:00 CET | Press release

Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership. Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India. Flowc

Infobip Joins EU Initiative to Boost Europe's Global Competitiveness13.2.2025 12:47:00 CET | Press release

Global cloud communications platform Infobip has officially signed the contract to join the IPCEI-CIS project, an EU-led initiative to create the next-generation global communications platform to increase Europe's international competitiveness. The signing took place at Infobip's campus in Zagreb, where Croatian Prime Minister Andrej Plenković participated in the event alongside Infobip's CEO Silvio Kutić. With this project, Europe aims to safeguard its digital and technological sovereignty, as many existing models that dominate the cloud infrastructure sector do not often align with EU data protection and transparency regulations. Croatian Prime Minister Andrej Plenković said: "Infobip is an example of Croatian technological excellence and global success. Its entry into the Project of Common European Interest (IPCEI) confirms its key role in European digital infrastructure. This project helps create a secure cloud infrastructure, supporting industries, companies, and public services a

Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions13.2.2025 10:00:00 CET | Press release

Ricardo has signed a multi-year deal to supply transmissions for Porsche 911s reimagined by Singer Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK. The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911. Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science. Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission

Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events13.2.2025 10:00:00 CET | Press release

Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/ (Graphic: Xsolla) “This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and cr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye